2026-06-01T19:50:23Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/336272026-02-03T11:31:03Zcom_10630_2254col_10630_37953

Carrasco-Hernández, Laura Jódar-Sánchez, Francisco Núñez-Benjumea, Francisco Moreno Conde, Jesús Mesa González, Marco Civit-Balcells, Antón Hors-Fraile, Santiago Parra-Calderón, Carlos L. Bamidis, Panagiotis D. Ortega Ruiz, Francisco 2024-09-27T09:24:32Z 2024-09-27T09:24:32Z 2020 Carrasco-Hernandez, L., Jódar-Sánchez, F., Núñez-Benjumea, F., Moreno Conde, J., Mesa González, M., Civit-Balcells, A., Hors-Fraile, S., Parra-Calderón, C. L., Bamidis, P. D., & Ortega-Ruiz, F. (2020). A Mobile Health Solution Complementing Psychopharmacology-Supported Smoking Cessation: Randomized Controlled Trial. JMIR mHealth and uHealth, 8(4), e17530. https://doi.org/10.2196/17530 https://hdl.handle.net/10630/33627 10.2196/17530 Objective: This study aimed to analyze the long-term efficacy of a mobile app supporting psychopharmacological therapy for smoking cessation and complementarily assess the involved innovative technology. Methods: A 12-month, randomized, open-label, parallel-group trial comparing smoking cessation rates was performed at Virgen del Rocío University Hospital in Seville (Spain). Smokers were randomly allocated to a control group (CG) receiving usual care (psychopharmacological treatment, n=120) or an intervention group (IG) receiving psychopharmacological treatment and using a mobile app providing artificial intelligence-generated and tailored smoking cessation support messages (n=120). The secondary objectives were to analyze health-related quality of life and monitor healthy lifestyle and physical exercise habits. Safety was assessed according to the presence of adverse events related to the pharmacological therapy. Per-protocol and intention-to-treat analyses were performed. Incomplete data and multinomial regression analyses were performed to assess the variables influencing participant cessation probability. Results: In the IG, abstinence was 2.75 times higher (adjusted OR 3.45, p=0.01) in the per-protocol analysis and 2.15 times higher (adjusted OR 3.13, p=0.002) in the intention-to-treat analysis. Lost data analysis and multinomial logistic models showed different patterns in participants who dropped out. Regarding safety, 14 of 120 (11.7%) IG participants and 13 of 120 (10.8%) CG participants had 19 and 23 adverse events, respectively (p=0.84). None of the clinical secondary objective measures showed relevant differences between the groups. Conclusions: The proposed mHealth solution complementing psychopharmacological therapy showed greater efficacy for achieving 1-year tobacco abstinence as compared with psychopharmacological therapy alone. eng open access Tabaquismo - Tratamiento A Mobile Health Solution Complementing Psychopharmacology-Supported Smoking Cessation: Randomized Controlled Trial journal article